BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Black Diamond Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Black Diamond Therapeutics\, Inc.
 's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05256290-2729@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Silevertinib: Phase 1/2 readout est. (NCT05256290)
DESCRIPTION:Silevertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma 
 or Non-Small Cell Lung Cancer With EGFR Mutations\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/si
 levertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05256290
URL:https://assetmemo.bio/drug/silevertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326566-2729@assetmemo.bio
DTSTAMP:20261121T011041Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Silevertinib: Phase 2 readout est. (NCT07326566)
DESCRIPTION:Silevertinib\, phase 2.\nStudy: Study of Silevertinib With Temo
 zolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT a
 nd EGFRvIII\nEstimated primary completion: November 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/silevertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07326566
URL:https://assetmemo.bio/drug/silevertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
